Table 1.
Patient demographics.
| Covariates | Non-PLND Group | PLND Group | p |
|---|---|---|---|
| Number | 605 | 605 | |
| Age (median, year, IQR) | 69 (64–73) | 68 (65–72) | 0.967 |
| Body mass index (median, kg/m2, IQR) | 23.4 (21.7–25.2) | 23.5 (21.7–25.6) | 0.200 |
| Initial PSA (median, ng/mL, IQR) | 7.002 (5.280–10.220) | 7.230 (5.300–10.344) | 0.454 |
| Biopsy Grade group (number, %) | 0.541 | ||
| 1 | 170 (28.1) | 168 (27.8) | |
| 2 | 272 (45.0) | 265 (43.7) | |
| 3 | 115 (19.0) | 121 (20.0) | |
| 4 | 40 (6.6) | 39 (6.4) | |
| 5 | 8 (1.3) | 13 (2.1) | |
| Clinical T stage (number, %) | 0.751 | ||
| T1 | 132 (21.8) | 135 (22.3) | |
| T2 | 463 (76.5) | 453 (74.7) | |
| T3 | 10 (1.7) | 18 (3.0) | |
| NCCN risk classification (number, %) | 0.139 | ||
| Low | 97 (16.0) | 84 (13.9) | |
| Intermediate | 426 (70.4) | 426 (70.2) | |
| High | 82 (13.6) | 96 (15.9) | |
| ECOG-PS (number, %) | 0.244 | ||
| 0 | 591 (97.7) | 586 (96.7) | |
| 1 | 14 (2.3) | 19 (3.1) | |
| 2 | 0 | 1 (0.2) | |
| Follow-up period (median, months, IQR) | 17.2 (8.9–32.6) | 24.7 (11.4–53.6) | <0.001 |
PLND, pelvic lymph node dissection; IQR, interquartile range; PSA, prostate-specific antigen; NCCN, National Comprehensive Cancer Network; ECOG-PS, Eastern Cooperative Oncology Group; T stage, tumor stage.